ProShare Advisors’s Kalaris Therapeutics, Inc. Common Stock KLRS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-611
| Closed | -$30.2K | – | 1977 |
|
|
2023
Q3 | $30.2K | Buy |
611
+111
| +22% | +$5.49K | ﹤0.01% | 1760 |
|
|
2023
Q2 | $39.1K | Buy |
500
+59
| +13% | +$4.62K | ﹤0.01% | 1793 |
|
|
2023
Q1 | $39.9K | Sell |
441
-68
| -13% | -$6.16K | ﹤0.01% | 1688 |
|
|
2022
Q4 | $60K | Buy |
509
+20
| +4% | +$2.36K | ﹤0.01% | 1721 |
|
|
2022
Q3 | $90K | Buy |
+489
| New | +$90K | ﹤0.01% | 1583 |
|
|
2022
Q2 | – | Sell |
-534
| Closed | -$84K | – | 2171 |
|
|
2022
Q1 | $84K | Sell |
534
-145
| -21% | -$22.8K | ﹤0.01% | 2062 |
|
|
2021
Q4 | $201K | Sell |
679
-90
| -12% | -$26.6K | ﹤0.01% | 2030 |
|
|
2021
Q3 | $443K | Sell |
769
-72
| -9% | -$41.5K | ﹤0.01% | 1281 |
|
|
2021
Q2 | $382K | Buy |
841
+105
| +14% | +$47.7K | ﹤0.01% | 1727 |
|
|
2021
Q1 | $396K | Buy |
736
+126
| +21% | +$67.8K | ﹤0.01% | 1611 |
|
|
2020
Q4 | $539K | Buy |
+610
| New | +$539K | ﹤0.01% | 1229 |
|